Abstract 5219
Background
Optimising quality of life (QoL) remains the central tenet of care in patients with incurable cancer, however determinants of this are not clear.
Methods
Multi-centre study conducted across 18 sites in Ireland and United Kingdom over a period of 5 years (2011-2016). Data collected included: patient demographics, Performance Status (ECOG-PS), weight loss (%WL) and skeletal muscle index (SMI) and skeletal muscle attenuation (MA) assessed by CT images, inflammatory markers [modified Glasgow Prognostic score (mGPS)] and QoL data (EORTC QLQ-30). The relationship between clinical and nutritional parameters with QoL was assessed using the Spearman rank correlation coefficient & multivariate binary logistic regression.
Results
Data were available on 1027 patients, of which 51% were male and the median age was 66 (IQR 57-74) years. Gastrointestinal cancer was most prevalent (40%) and 87% of patients had metastatic disease. %WL, ECOG-PS and mGPS were significantly correlated with deteriorating QoL functional & symptom scales (all p < 0.001). On multivariate regression analysis, >10% WL (OR 2.69 [95% CI: 1.63-4.42]), ECOG-PS 3-4 (OR 14.33 [95% CI: 6.76- 30.37]) and mGPS score 2 (OR 1.58 [95% CI: 1.09- 2.29]) were independently associated with poorer summary QoL score. WL & mGPS were also independently associated with poor physical function, fatigue and appetite loss (all p < 0.05). Low MA was independently associated with poor physical function (OR 1.67 [95% CI: 1.09-2.56]), but not with fatigue, appetite or QoL summary score.
Conclusions
The findings indicate that QoL is determined in part by WL, ECOG-PS and systemic inflammation in patients with advanced cancer. Although muscle parameters were associated with some QoL domains, no significant independent association with fatigue, appetite loss or QoL summary score was observed. Identifying early predictors of poor QoL may allow the identification of patients who may benefit from early referral to palliative care, which has been shown to improve QoL.
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3690 - PD-L1 expression in resected undifferentiated pleomorphic sarcoma and its clinical implications
Presenter: Kyoungmin Lee
Session: Poster Display session 1
Resources:
Abstract
2013 - PD-L1 expression as a potential therapeutic target and prognostic biomarker in well-differentiated and dedifferentiated liposarcoma.
Presenter: Heejung Chae
Session: Poster Display session 1
Resources:
Abstract
5021 - Soft tissue sarcomas express a distinct mRNA immune profile
Presenter: Viktor Grünwald
Session: Poster Display session 1
Resources:
Abstract
3029 - The molecular landscape of fusion genes in endometrial stromal sarcomas include three nosological entities with different natural history
Presenter: Mehdi Brahmi
Session: Poster Display session 1
Resources:
Abstract
3914 - Clinical validation of a novel assay for the detection of diagnostic alterations in sarcomas
Presenter: Lauren Mc Connell
Session: Poster Display session 1
Resources:
Abstract
1912 - A prospective correlative trial of personalized patient-derived xenograft (PDX) as avatars for drug therapy in patients with metastatic or recurrent soft tissue sarcomas (STS).
Presenter: Kanan Alshammari
Session: Poster Display session 1
Resources:
Abstract
5097 - Fusion of immortalized myoblasts induces genomic instability that drives tumor development and progression.
Presenter: Candice Merle
Session: Poster Display session 1
Resources:
Abstract
1383 - let-7a suppress Ewing sarcoma CSCs' malignant phenotype through forms a positive feedback regulation loop with lin28 via STAT3
Presenter: Xu Jiang
Session: Poster Display session 1
Resources:
Abstract
3386 - Myoepithelial Tumors of Soft Tissues and Extraskeletal Myxoid Chondrosarcomas feature a distinct transcriptional pattern
Presenter: Dominga Racanelli
Session: Poster Display session 1
Resources:
Abstract
1844 - In Vivo Efficacy and Enhanced Tumor Accumulation of Liposomal Vinorelbine (TLC178) in Human Sarcoma Xenograft Mice Model
Presenter: Wan-ni Yu
Session: Poster Display session 1
Resources:
Abstract